ribavirin / Generic mfg. - LARVOL DELTA

Discovery of potential RdRp catalytic domain inhibitors against Crimean-Congo hemorrhagic fever virus from Andrographis paniculata via LC-MS/MS profiling and computational approaches. (PubMed, In Silico Pharmacol) - "Molecular docking revealed strong binding affinities of bisandrographolide (- 8.212 kcal/mol), andrographiside (- 7.659 kcal/mol), 3-O-β-D-glucopyranosyl-andrographolide (- 7.653 kcal/mol), andrographidin A (- 7.540 kcal/mol) and neoandrographolide (- 7.353 kcal/mol) towards the catalytic domain of RdRp which is comparable to standard Ribavirin (- 8.314 kcal/mol)...Collectively, results suggest that Andrographis paniculata phytoconstituents, particularly andrographolide diterpenes lactones possess promising inhibitory potential against catalytic domain of CCHFV RdRp and may serve as lead candidates for antiviral drug development. Further mechanistic studies are needed to elucidate exact mode of RdRp catalytic domain inhibition while in vitro and in vivo validation is crucial to confirm their therapeutic potential and translational relevance."

Journal • Hematological Disorders

Punicalin targets RSV glycoprotein and fusion protein at non-overlapping sites to prevent viral escape. (PubMed, Cell Rep Med) - "PUN inhibits the evaluated RSV-A and RSV-B strains, including a clinical isolate, and retains activity against strains resistant to ziresovir, ribavirin, nirsevimab, and palivizumab. These regions do not overlap known resistance hotspots. In RSV-infected mice, nebulized PUN provides sustained respiratory exposure, reduces lung viral loads and pathology, and attenuates inflammatory responses."

Journal • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections

Third Time's the Charm: Virologic Suppression After 2 Consecutive DAA Failures in Chronic Hepatitis C (ACG 2026) - "Introduction: Direct-acting antivirals achieve sustained virologic response (SVR) in over 95% of patients with chronic hepatitis C virus (HCV) infection, so sequential failure of multiple regimens is rare, and evidence guiding retreatment after sofosbuvir/velpatasvir/voxilaprevir failure is limited and extrapolated from small studies.[1] We present a non-cirrhotic genotype 1a patient with an NS5A L31M resistance-associated variant (RAV) who failed two sequential regimens but achieved on-treatment suppression with an extended course plus ribavirin...L31M was classified as conferring possible resistance to daclatasvir, elbasvir, ledipasvir, and ombitasvir, but no determinable impact on velpatasvir or pibrentasvir...Third, the recommendation for this extended regimen after voxilaprevir failure rests on a retrospective study of only four patients, so each real-world case adds to a thin evidence base. Suppression after two failed courses suggests extended duration and..."

Cardiovascular • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Orthopedics • Portal Hypertension

Hepatitis E Virus Genotype 3: An Under-Recognized Mimic of Cellular Rejection in a North American Liver Transplant Patient (ACG 2026) - "He was maintained on everolimus with stable trough levels...Ribavirin was initiated at 400 mg daily and titrated to 600 mg...Given that 60â70% of OLT recipients with HEV progress to chronicity and accelerated allograft cirrhosis, early diagnosis via HEV RNA PCR is essential. HEV must be excluded before escalating immunosuppression for suspected ACR, as intensified immunosuppression risks worsening viral replication and fibrotic progression."

Clinical • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Prior Decompensation Events and Outcomes in Patients Treated for Cirrhosis Secondary to Chronic Hepatitis C (ACG 2026) - "This retrospective study evaluated patients' decompensating events prior to initiating treatment and outcomes after SVR (sustained virologic response) using the current guideline recommended treatment regimens of sofosbuvir-velpatasvir (sof-vel) and ledipasvir-sofosbuvir (led-sof) with the addition of ribavirin (rbv). The study comprised a total of 41 patients (32 males). Prior to treatment, 3 patients were Child-Pugh class C and the remaining were Child-Pugh class B, with a mean MELD of 14.5 ± 4.8 . 22 patients (53%) were treated with sof-vel-rbv, 5 with led-sof-rbv, 8 with led-sof, 6 with sof-vel."

Clinical • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Solid Tumor

A decade of chronic hepatitis E treatment: Ribavirin effectiveness, safety, and the association of Torque Teno Virus load with treatment outcomes. (PubMed, J Clin Virol) - "Ribavirin is effective for chronic HEV, but treatment-limiting toxicity is common. Adequate dosing appears critical for achieving SVR. TTV load did not reliably predict treatment outcome, underscoring the need for further research into immunological and virological predictors of response."

Journal • Hematological Disorders • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Eugenol-Derived Piperazine Mannich Bases as Selective Inhibitors of Mayaro Virus: In Vitro Antiviral Evaluation and Mechanistic Insights. (PubMed, J Med Virol) - "Notably, compound D7 demonstrated low-micromolar anti-MAYV inhibition (EC50 = 14.43 μM; SI > 16.6), surpassing ribavirin by more than thirty-fold in relative potency...Virucidal assays confirmed that D7 does not directly inactivate viral particles. These findings identify D7 as a promising antiviral lead compound and provide a foundation for further mechanistic, optimization, and in vivo studies aimed at developing anti-alphavirus therapeutics."

Journal • Preclinical • Chikungunya • Infectious Disease

Hepatitis C in Chronic Kidney Disease After the DAA Revolution: Clinical Decisions, Transplantation, and Implementation Challenges. (PubMed, J Clin Med) - "Present evidence supports using the recommended DAA regimens without renal dose adjustment, while ribavirin needs dose modification when kidney function is reduced and can result in hemolytic anemia. Antiviral therapy is the first-line treatment for HCV-associated glomerular disease, while rituximab-based immunosuppression is largely reserved for severe, rapidly progressive, or persistent cryoglobulinemic vasculitis. Future progress will depend less on proving antiviral efficacy and more on closing the gaps between screening, confirmatory testing, starting treatment, transplantation pathways, and long-term follow-up, gaps that stem from inequities in diagnostic infrastructure, drug reimbursement, and healthcare-system organization as much as from any remaining biomedical uncertainty."

Journal • Review • Chronic Kidney Disease • Complement-mediated Rare Disorders • Fibrosis • Glomerulonephritis • Hematological Disorders • Hepatitis C • Immunology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Transplantation • Vasculitis

Clinician-Reported Respiratory Viral Testing and Intended Management of Community-Acquired Respiratory Viral Infections in Haematology and Haematopoietic Cell Transplantation: An International Exploratory Survey. (PubMed, Diagnostics (Basel)) - "RSV practice was heterogeneous: systemic ribavirin was considered by 45/96 (46.9%) respondents, including 34/96 (35.4%) when guided by an immunodeficiency score...Because sampling was non-probability-based and respondent groups were small and unevenly distributed, the findings should not be interpreted as representative estimates of international practice. IAV testing was most consistently linked to established treatment and prevention, RSV showed greater therapeutic and preventive heterogeneity, and HMPV/HPIV testing primarily informed infection control, monitoring and antimicrobial stewardship."

Journal • Critical care • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Oncology • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Oral MDL-001 a Universal Direct Acting Antiviral for Influenza Like Illness(ILI): In Vivo Equivalence or Superiority to Oseltamivir, Nirmatrelvir and Remdesivir, In Vitro Superiority to Ribavirin (IDWeek 2026) - No abstract available

Head-to-Head • Preclinical • Infectious Disease • Influenza

Whole-Genome Analysis of HEV Under Sequential Ribavirin Pressure Reveals Early Minor Variants Predicting Resistance. (PubMed, J Med Virol) - "Importantly, D1384N and G1634R were already detectable at low allele frequencies after the first treatment cessation and subsequent rebound, showing that the study of minor variant populations can be early predictors for the development of RBV resistance. These findings underscore the genomic plasticity of HEV under antiviral pressure and highlight the value of deep variant profiling for anticipating RBV treatment failure."

Journal • Infectious Disease • Inflammation

Reduction of immunosuppressants fails to clear hepatitis E virus infection in a heart transplant recipient. (PubMed, IDCases) - "The patient is administered ribavirin at a dose of 600 mg/d, and by the third month, the viral load significantly decreases. By the fourth month, HEV infection is successfully cleared, liver function parameters returned to normal, and no viral reactivation is observed through the eighth month. This work highlights therapeutic approaches for managing HEV infection in solid organ transplantation (SOT) recipients."

Journal • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Lethal C57BL/6 mouse model for Yezo virus infection and antiviral therapeutic evaluation. (PubMed, Emerg Microbes Infect) - "Antiviral evaluation demonstrated that both favipiravir and ribavirin significantly suppressed in vivo YEZV replication, improved survival, and reduced hepatic viral burden. Collectively, this model establishes a rigorously validated platform for mechanistic studies of YEZV pathogenesis and the preclinical evaluation of antiviral therapeutics."

Journal • Preclinical • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Leukopenia • Liver Failure • Thrombocytopenia

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. (PubMed, J Clin Oncol) - "HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting."

Journal • Hematological Disorders • Hematological Malignancies • Hepatitis C • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Scaffold Hopping for Pesticide Discovery: Design, Synthesis, and Biological Activity Research of Novel Raspberry Ketone Derivatives. (PubMed, J Agric Food Chem) - "Most compounds exhibited better antiviral activity than ribavirin; in particular, compounds 3iand 5h-5j showed significantly higher antiviral activity (EC50: 144-199 μg/mL) than ningnanmycin (EC50: 235 μg/mL) and thus emerged as novel antiviral candidates...Additionally, these compounds displayed broad-spectrum fungicidal activity against six plant pathogens and met pesticide-likeness criteria in ADME predictions. This research advances the development of raspberry ketone derivatives as green pesticides."

Journal

Repurposing ribavirin for oncology: Integrating metabolism, signaling, and translational control. (PubMed, J Pharmacol Exp Ther) - "SIGNIFICANCE STATEMENT: This review theorizes ribavirin as a systems-level anticancer agent by integrating its effects on guanine nucleotide metabolism, oncogenic signaling, and eukaryotic translation initiation factor 4E-dependent translation into a unified metabolic-signaling-translation axis. In addition, it identifies the disparities in the mechanistic literature, which may assist in designing future studies."

Journal • Review • Oncology • EIF4E

Letter to the Editor on: "Nosocomial Respiratory Virus Infections in Hematologic Malignancies: Risk Factors for Progression to Lower Respiratory Tract Infection". (PubMed, Transplant Cell Ther) - "We raise three methodological concerns: (1) the landmark analysis used to evaluate URTI-stage ribavirin therapy excludes patients who progressed or died before landmark time points, introducing selection bias by conditioning on a collider; (2) antiviral therapy analyses are severely underpowered (only 15 PIV and 9 RSV treated patients), with wide confidence intervals precluding definitive conclusions and substantial Type II error risk; and (3) combining glucocorticoid exposures from different indications (short-course pulse vs. prolonged therapy) may mask heterogeneous effects on immune function and viral progression. We commend the authors' risk stratification framework while urging cautious interpretation of antiviral efficacy data and recommending future prospective studies with adequate sample sizes and refined corticosteroid characterization."

Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Respiratory Diseases • Respiratory Syncytial Virus Infections

Measles: A Narrative Review of Current Therapeutic Options and Implications for the Future. (PubMed, Viruses) - "Despite the availability of a safe and effective measles vaccine for several decades, measles remains a significant cause of morbidity and mortality worldwide, causing 95,000 deaths in 2024 alone...There are few reports indicating that repeated remdesivir courses, as well as intraventricular or intrathecal ribavirin or IFN, may temporarily stabilize the neurologic status of patients with subacute sclerosing panencephalitis...Overall, the development of antiviral agents against measles has been extremely slow. Therapeutic agents against measles are urgently needed."

Clinical • Journal • Review • CNS Disorders • Infectious Disease • Measles

Extra-Hepatic Manifestations of Hepatitis E Virus (HEV): A Narrative Review on Meningoencephalitis. (PubMed, Life (Basel)) - "Ribavirin remains the antiviral mainstay, but viral persistence within CNS sanctuary sites raises concerns about treatment adequacy and relapse; emerging antiviral and immunomodulatory strategies remain under investigation. HEV should be systematically considered in the diagnostic workup of unexplained neurological syndromes, regardless of overt hepatitis; heightened clinical awareness remains the most immediately actionable step toward reducing the burden of this still under-recognized condition."

Journal • Review • CNS Disorders • Hepatology • Infectious Disease • Inflammation • Pain

Longitudinal Outcomes and Ribavirin Use in Lung Transplant Recipients with Respiratory Syncytial Virus or Human Metapneumovirus Infection: A Real-World Multicenter Cohort Study. (PubMed, Life (Basel)) - "RSV and hMPV infections after LT were frequently associated with lower respiratory involvement and lung function decline. In this observational cohort, ribavirin use was not independently associated with 90-day FEV1 change; however, residual confounding and limited statistical power preclude conclusions regarding treatment efficacy."

Journal • Real-world evidence • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial completion date: Jul 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Nov 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model. (PubMed, Trop Med Infect Dis) - "Eligible patients received pangenotypic sofosbuvir/velpatasvir for 12 weeks, with ribavirin added for cirrhosis. Among 6719 evaluable for SVR12, 6474 (96.4%) achieved cure. This simplified, domestically financed, decentralized test-to-treat model achieved WHO-target-level diagnosis, treatment, and cure rates at provincial scale, offering a scalable framework for HCV micro-elimination in low- and middle-income countries."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy (ASH 2025) - "RSV-specifictreatment (ribavirin ± corticosteroids/IVIG) was administered to 8 patients, all with severe infection,except one who received ribavirin for URTI...This is the first multicenter study with over 600 CAR-T recipients to systematically evaluate RSV-specificepidemiology following CAR-T therapy. The infection incidence and outcomes were comparable to thosereported after HCT, with 6% of recipients diagnosed and almost 30% progressing to LRTI, even beyondday +100. Older age and profound lymphopenia were associated with severe disease."

CAR T-Cell Therapy • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4

How drug invention transformed hepatitis C from a chronic infection into a curable disease (ACS-Fall 2026) - "In the early 2000s, an estimated 170 million people worldwide were chronically infected with hepatitis C virus (HCV), and therapeutic options were limited to pegylated interferona-α in combination with ribavirin - a regimen characterized by modest efficacy, prolonged treatment duration, and significant adverse effects...From 2014 to 2023, these innovations translated into significant clinical impact, with an estimated 12.7 million patients worldwide receiving curative DAA treatment1. Collectively, the invention of HCV DAAs represents a landmark achievement in antiviral drug development and serves as a paradigm for rapid translation of molecular insight into curative therapies."

Hepatitis C • Hepatology • Infectious Disease • Inflammation

Adjunctive palivizumab with ribavirin for respiratory syncytial virus infection during the early peri-transplant period in adult allogenic hematopoietic stem cell transplant recipients: Case series. (PubMed, IDCases) - "Adjunctive palivizumab appears to be safe and may be a useful therapeutic option for HSCT recipients with RSV infection during the peri-transplant period. Larger prospective studies are needed to define the optimal role, timing, and route of palivizumab administration in this high-risk population."

Journal • Bone Marrow Transplantation • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation